Digital Therapeutics/DTx Market by Offering, Application, Revenue, Channel, End User - Global Forecast to 2031

Digital Therapeutics Market to Reach USD 35.37 Billion by 2031, Growing at a 26.4% CAGR. AI innovation, chronic disease prevalence, remote care demand and expanding digital health infrastructure are accelerating global market growth.

Dublin, Sept. 18, 2026 (GLOBE NEWSWIRE) -- "Digital Therapeutics/DTx Market by Offering, Application, Revenue, Channel, End User - Global Forecast to 2031" has been added to ResearchAndMarkets.com's offering.

The global digital therapeutics market is projected to grow from USD 10.95 billion in 2026 to USD 35.37 billion by 2031, registering a compound annual growth rate of 26.4% during the forecast period. Growth is being driven by the increasing prevalence of chronic diseases, demand for personalized and remote patient care, and pressure to improve clinical outcomes while reducing healthcare costs.

Healthcare providers, payers and employers are increasing their adoption of evidence-based digital therapeutics for the prevention, management and treatment of diabetes, obesity, cardiovascular diseases, musculoskeletal disorders, insomnia and mental health conditions. Advances in artificial intelligence, remote patient monitoring, wearable technologies and interoperable digital health infrastructure are also improving personalization, accessibility, patient engagement and value-based healthcare delivery.

Regulatory and reimbursement support continues to strengthen. In March 2025, the European Health Data Space Regulation entered into force, establishing a harmonized framework for the secure exchange and secondary use of electronic health data across the European Union. The framework is expected to support the integration and scalability of digital therapeutics.

Market expansion may be moderated by fragmented reimbursement policies, evolving regulatory requirements, data privacy and cybersecurity concerns, limited awareness among healthcare professionals, and the need for robust clinical and real-world evidence demonstrating long-term therapeutic and economic value.

Hospitals Held the Largest End-User Share in 2025

Hospitals accounted for the largest share of the digital therapeutics market by end user in 2025. Adoption is increasing as hospitals integrate digital therapeutic solutions into multidisciplinary care pathways for chronic disease management, mental health, rehabilitation and post-acute care.

These solutions complement conventional therapies, support continuous remote monitoring, improve patient engagement and strengthen treatment adherence beyond inpatient settings. The transition toward value-based care, efforts to reduce hospital readmissions, and demand for personalized, data-driven interventions are further supporting deployment across hospital networks. Integrated digital health infrastructure, established clinical workflows and collaboration with technology developers and healthcare providers are enabling implementation at scale.

B2C Sales Channel to Register the Fastest Growth

The B2C segment is expected to record the highest growth rate among digital therapeutics sales channels through 2031. Increasing consumer awareness, demand for convenient self-management tools and acceptance of preventive and wellness-focused care are supporting this expansion.

Consumers are adopting mobile applications and connected devices to manage obesity, sleep disorders, stress, anxiety, diabetes and other lifestyle-related conditions. Smartphone penetration, wearable health technologies and subscription-based digital health platforms are making digital therapeutics more accessible to broader populations. AI-enabled personalization, behavioral coaching, real-time health insights, direct-to-consumer marketing and expanding digital distribution channels are also improving engagement and long-term adherence.

Asia Pacific Is Projected to Achieve the Highest Regional Growth Rate

Asia Pacific is expected to register the fastest digital therapeutics market growth during the forecast period. Key drivers include the rising burden of chronic disease, rapid healthcare digitalization, increasing smartphone adoption and government initiatives supporting digital health infrastructure.

China, Japan, India, South Korea, Singapore and Australia are expanding investments in telehealth, remote patient monitoring, AI-enabled healthcare and digital disease management. These investments are intended to improve healthcare accessibility and address diabetes, cardiovascular diseases, obesity and mental health disorders.

Regional growth is also being supported by digital health startups, collaborations between healthcare providers and technology companies, and expanding reimbursement support. In February 2024, TruDoc Healthcare acquired Wellthy Therapeutics, one of Asia's leading digital therapeutics companies. The transaction combined Wellthy's clinically validated digital therapeutics platform with TruDoc's virtual primary care and remote healthcare services, strengthening TruDoc's capabilities across the Gulf Cooperation Council region while supporting expansion into India. The acquisition reflects increasing strategic investment in digital therapeutics and reinforces Asia Pacific's role in digital health innovation and commercialization.

Key Digital Therapeutics Market Players

Leading companies covered in the competitive assessment include Teladoc Health, Inc. of the US; Noom, Inc. of the US; Omada Health Inc. of the US; Hinge Health, Inc. of the US; DarioHealth Corp. of the US; and Sword Health, Inc. of Portugal.

The analysis evaluates company market shares, product offerings, capabilities and growth strategies, including contracts, partnerships, agreements, product and service launches, mergers and acquisitions. It also examines recent industry developments and emerging startups across the digital therapeutics ecosystem.

Research Coverage

The digital therapeutics market report provides analysis across the following segments:

• Offering: Software AG and platforms, therapeutic programs, and immersive and Interface -based therapeutics
• Product type: Prescription and non-prescription digital therapeutics
• Application: Treatment and care-related applications and preventive applications
• Revenue model: Subscription-based, enterprise licensing and SaaS, and outcome- or value-based models
• Sales channel: B2B and B2C
• End user: Healthcare providers, payers, employers, patients and individuals, and other end users
• Region: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa

The report assesses major market drivers, restraints, opportunities and challenges. Drivers include chronic and behavioral health conditions, value-based and patient-centered care, smartphone adoption, digital health infrastructure, clinical evidence and regulatory recognition. Restraints include limited reimbursement, inconsistent payment pathways and regulatory complexity. Opportunities include expansion into new therapeutic areas, AI integration, personalized medicine, and partnerships with pharmaceutical and healthcare organizations. Key challenges include sustaining patient engagement and adherence and demonstrating long-term clinical and economic value.

Additional coverage includes upcoming technologies, research and development, product launches, emerging markets, product portfolios, geographic expansion, recent investments and market diversification.

Primary Research Participant Breakdown

• By company type: Tier 1, 34%; Tier 2, 46%; and Tier 3, 20%
• By designation: C-level, 35%; director-level, 25%; and others, 40%
• By region: North America, 30%; Europe, 45%; Asia Pacific, 20%; Middle East and Africa, 3%; and Latin America, 2%

The report is designed to help established companies, new entrants and smaller firms evaluate digital therapeutics market opportunities, identify competitive priorities and develop strategies for product innovation, market development, diversification, partnerships and geographic expansion.

Key Attributes:

Report Attribute	Details
No. of Pages	415
Forecast Period	2026 - 2031
Estimated Market Value (USD) in 2026	$10.95 Billion
Forecasted Market Value (USD) by 2031	$35.37 Billion
Compound Annual Growth Rate	26.4%
Regions Covered	Global

Key Topics Covered:

Market Dynamics

• Drivers
  • Rising Prevalence of Chronic and Behavioral Health Conditions
  • Shift Toward Value-Based and Patient-Centered Care
  • Expansion of Smartphone Adoption and Digital Health Infrastructure
  • Growing Clinical Evidence and Regulatory Recognition
• Challenges
  • Restraints
    • Limited Reimbursement and Inconsistent Payment Pathways
    • Regulatory Complexity and Evolving Approval Frameworks
  • Sustaining Long-Term Patient Engagement and Adherence
  • Demonstrating Long-Term Clinical and Economic Value
• Case Studies
• Industry Trends
• Opportunities
  • Expansion Into New Therapeutic Areas
  • Integration With AI and Personalized Medicine
  • Increasing Partnerships With Pharmaceutical and Healthcare Organizations

Company Profiles

• Teladoc Health, Inc.
• Noom, Inc.
• Hinge Health, Inc.
• Omada Health Inc.
• Dariohealth Corp.
• Sword Health, Inc.
• Resmed
• Virta Health Corp.
• Welldoc, Inc.
• Click Therapeutics, Inc.
• Sidekick Health
• Akili, Inc.
• Appliedvr, Inc.
• Wellthy Therapeutics Pvt. Ltd.
• Headspace Inc.
• Lark Technologies, Inc.
• Xrhealth
• Amalgam Rx, Inc.
• Aptar Digital Health
• Canary Health
• Freespira
• Mindable Health GmbH
• Get.on Institut Fur Online Gesundheitstrainings GmbH
• Cognifit Inc.
• 2Morrow Inc.

For more information about this report visit https://www.researchandmarkets.com/r/4rct0k

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: 
CONTACT: ResearchAndMarkets.com 
         Laura Wood, Senior  Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900